TABLE 3.
Baseline characteristics and outcomes of Achromobacter xylosoxidans-colonised patients with cystic fibrosis stratified by Pseudomonas aeruginosa co-isolation status
| Characteristics or outcomes | Co-isolation status | p-value | |
| Ax+ Pa− (n=9) | Ax+ Pa+ (n=27) | ||
| Baseline characteristics | |||
| Female | 5 (55.6) | 14 (51.9%) | 1.00 |
| Homozygous F508del | 3 (33.3) | 11 (44.0) | 0.70 |
| Pancreatic insufficiency | 6 (66.7) | 24 (88.9) | 0.15 |
| Long-term azithromycin | 3 (33.3) | 11 (40.7) | 1.00 |
| MRSA isolation | 1 (11.1) | 7 (25.9) | 0.65 |
| Allergic bronchopulmonary aspergillosis | 5 (55.6) | 13 (48.1) | 1.00 |
| Age years | 26.0 (21.0–36.0) | 22.0 (20.0–28.0) | 0.30 |
| BMI kg·m−2 | 18.0 (17.7–20.8) | 19.6 (17.7–21.6) | 0.83 |
| Suppressive antibiotherapy in the previous year | 1 (11.1) | 18 (66.7) | 0.006 |
| Intravenous antibiotherapy courses in the previous year | 0.0 (0.0–2.0) | 2.0 (1.0–4.0) | 0.099 |
| Outcomes | |||
| Lung function | |||
| ΔFEV1 %·year−1 | −2.66±0.98 | −6.05±0.54 | 0.003 |
| ΔFEV1 mL·year−1 | −105.4±32.77 | −169.2±18.68 | 0.092 |
| Number of exacerbations: | |||
| Year before baseline, median (IQR) | 2.0 (1.0–2.0) | 3.0 (1.0–4.0) | 0.11 |
| Year after baseline, median (IQR) | 2.0 (1.0–3.0) | 3.0 (2.0–5.0) | 0.037 |
| Years 1 and 2 after baseline, median (IQR)# | 5.0 (3.0–8.0) | 6.5 (4.0–9.0) | 0.26 |
| Years 1–3 after baseline, median (IQR)# | 8.0 (7.0–12.0) | 9.0 (6.0–14.0) | 0.40 |
Data are presented as n (%), median (interquartile range) or β±se (slope of change calculated from the baseline (time of bacterial detection)), unless otherwise stated. MRSA: methicillin-resistant Staphylococcus aureus; BMI: body mass index; FEV1: forced expiratory volume in 1 s.#: cumulative number of exacerbations.